Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00939523 · OUTCOME

Number of Participants With 50% Reduction in Prolactin Levels

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy · Source last updated 2020-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
every month, up to 6 months

What was measured

50% reduction in prolactin level measured monthly on 6 months therapy compared to baseline level.

Analysis population: There were 6 prolactinomas and 3 nonfunctioning tumors in this trial. Prolactin results are only reported for the prolactinomas.

Groups in this outcome

Lapatinib

All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lapatinib6

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Lapatinib1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
50% reduction in prolactin level measured monthly on 6 months therapy compared to baseline level.
groups
  1. description
    All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.
    id
    OG000
    title
    Lapatinib
param Type
COUNT_OF_PARTICIPANTS
population Description
There were 6 prolactinomas and 3 nonfunctioning tumors in this trial. Prolactin results are only reported for the prolactinomas.
reporting Status
POSTED
time Frame
every month, up to 6 months
title
Number of Participants With 50% Reduction in Prolactin Levels
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice